TABLE OF CONTENTS

Lay Summary Page 2
Scientific discussion Page 3
Steps taken for assessment Page 11
Steps taken after authorisation – summary Page 12
Summary of Product Characteristics
Product Information Leaflet
Labelling
OXALIPLATIN 5MG/ML POWDER FOR SOLUTION FOR INFUSION
PL 18727/0010

LAY SUMMARY

On 25th February 2009, the MHRA granted Fresenius Kabi Oncology Plc a Marketing Authorisation (licence) for Oxaliplatin 5mg/ml Powder for Solution for Infusion (PL 18727/0010). Oxaliplatin is an anti-cancer drug and is used to treat cancer of the large bowel (colon and rectum). Oxaliplatin is used in combination with other anti-cancer medicines called 5-fluorouracil (5-FU) and leucovorin (folinic acid).

No new or unexpected safety concerns arose from this application and it was, therefore, judged that the benefits of taking Oxaliplatin 5mg/ml Powder for Solution for Infusion outweigh the risks; hence a Marketing Authorisation has been granted.
SCIENTIFIC DISCUSSION

TABLE OF CONTENTS

Introduction Page 4
Pharmaceutical assessment Page 5
Preclinical assessment Page 8
Clinical assessment (including statistical assessment) Page 9
Overall conclusions and risk benefit assessment Page 10
INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the UK granted a marketing authorisation for the medicinal product Oxaliplatin 5mg/ml Powder for Solution for Infusion (PL 18727/0010) to Fresenius Kabi Oncology Plc on 25th February 2009. This prescription only medicine is used in combination with 5-fluorouracil (5-FU) and folinic acid (FA) for the following indications:

- Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor
- Treatment of metastatic colorectal cancer.

This application for Oxaliplatin 5mg/ml Powder for Solution for Infusion is submitted as an abridged application according to Article 10.1 of Directive 2001/83/EC, claiming to be a generic medicinal product to Eloxatin 5mg/ml Powder for Solution for Infusion, first authorised to Sanofi-Synthelabo Limited in France in April 1996.

The product contains the active substance oxaliplatin, an antineoplastic active substance, a third-generation cisplatin analogue (a class of platinum-based compounds) with important difference in the molecule, and hence in the DNA adducts formed, confers a different spectrum of activity compared with cisplatin.

Oxaliplatin exhibits a wide spectrum of both in vitro cytotoxicity and in vivo antitumour activity in a variety of tumour model systems including human colorectal cancer models. Oxaliplatin also demonstrates in vitro and in vivo activity in various cisplatin resistant models. A synergistic cytotoxic action has been observed in combination with 5-fluorouracil both in vitro and in vivo.
PHARMACEUTICAL ASSESSMENT

DRUG SUBSTANCE
Oxaliplatin
INN: Oxaliplatin
Chemical name: \((SP-4-2)-[(1R,2R)-\text{Cyclohexane-1,2-diamine-}\kappa N\kappa' N']\)
\[\text{[ethanedioato(2)-}\kappa O\kappa'O^2]\text{platinum.}\]

Structure:

Physical form: white or almost white, crystalline powder.
Solubility: slightly soluble in water, very slightly soluble in methanol, practically insoluble in ethanol.

Molecular formula: \(\text{C}_8\text{H}_{14}\text{N}_2\text{O}_4\text{Pt}\)
Molecular weight: 397.3

Oxaliplatin is the subject of a European Pharmacopoeia monograph.

An Active Substance Master File (ASMF) has been provided covering the manufacture and control of the active substance oxaliplatin.

Synthesis of the drug substance from the designated starting materials has been adequately described, and appropriate in-process controls and intermediate specifications are applied. Satisfactory specification tests are in place for all starting materials and reagents, and these are supported by relevant certificates of analysis.

All potential known impurities have been identified and characterised. Appropriate proof of structure data has been supplied for the active pharmaceutical ingredient.

An appropriate specification is provided for the active substance oxaliplatin. Analytical methods have been appropriately validated and are satisfactory for ensuring compliance with the relevant specifications. Batch analysis data are provided and comply with the proposed specification.

Satisfactory certificates of analysis have been provided for working standards used by the active substance manufacturer and finished product manufacturer.

The specifications and typical analytical test reports are provided and are satisfactory.

Satisfactory specifications and certificates of analysis have been provided all aspects of the container-closure system. A declaration has been provided that the primary packaging complies with current regulations concerning contact with foodstuff.
An appropriate retest period has been proposed based on stability data submitted for the active substance oxaliplatin.

**DRUG PRODUCT**

**Other ingredients**

Other ingredients consist of pharmaceutical excipients nitrogen, lactose monohydrate and water for injection. All the ingredients comply with their relevant European Pharmacopoeia monographs.

None of the excipients contain materials of animal or human origin, with the exception of lactose monohydrate. The supplier of lactose monohydrate has confirmed that the lactose used is sourced from healthy animals under the same conditions as milk for human consumption.

**Product development**

The objective of the development programme was to produce a product that could be considered a generic medicinal product of Eloxatin 5mg/ml Powder for Solution for Infusion (Sanofi-Synthelabo Limited, April 1996.)

The applicant has provided a suitable product development section. Justifications for the use and amounts of each excipient have been provided and are valid. Comparative impurity profiles have been provided for the finished product versus the reference product Eloxatin 5mg/ml Powder for Solution for Infusion (Sanofi-Synthelabo Limited).

**Manufacture**

A description and flow-chart of the manufacturing method has been provided.

In-process controls are satisfactory based on process validation data and controls on batches of the finished product.

**Finished product specification**

The finished product specification is satisfactory. Test methods have been described and have been adequately validated, as appropriate. Batch data have been provided and comply with the release specification. Certificates of analysis for all working standards used have been provided and are satisfactory.

**Container-Closure System**

The product is packaged in clear, type I, glass vials sealed with Lyotec rubber stoppers.

Specifications and certificates of analysis for the packaging types used have been provided. All primary product packaging complies with European Pharmacopoeia monograph 3.2.1 (glass containers for pharmaceutical use). The product is packaged in sizes of 30ml and 50ml, containing 50mg and 100mg of oxaliplatin, respectively.

**Stability**

Finished product stability studies have been conducted in accordance with current guidelines. Based on the results, a shelf-life of 2 years for an opened product has been set with no special precautions for storage.
After dilution of the product, the solution for infusion should be used immediately, otherwise in-use storage time should be no longer than ‘20°C to 25°C up to 6 hours and 24 hours at 2°C to 8°C unless dilution has taken place in controlled and validated aseptic conditions.’

**ADMINISTRATIVE**

**Expert Report**
A pharmaceutical expert report has been written by a suitably qualified person and is satisfactory.

**Summary of Product Characteristics (SPC)**
This is pharmaceutically satisfactory.

**Labelling**
These are pharmaceutically satisfactory.

**Patient Information Leaflet (PIL)**
This is pharmaceutically satisfactory.

A package leaflet has been submitted to the MHRA along with results of consultations with target patient groups ("user testing"), in accordance with Article 59 of Council Directive 2001/83/EC, as amended. The results indicate that the package leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains.

**MAA Form**
This is pharmaceutically satisfactory.

**Conclusion**
It is recommended that a Marketing Authorisation is granted for this application.
PRECLINICAL ASSESSMENT

This application for Oxaliplatin 5mg/ml Powder for Solution for Infusion was submitted as an abridged application according to Article 10.1 of Directive 2001/83/EC, claiming to be a generic medicinal products of Eloxatin 5mg/ml Powder for Solution for Infusion, first authorised to Sanofi-Synthelabo Limited in France in April 1996.

No new preclinical data have been supplied with this application and none are required for applications of this type.
CLINICAL ASSESSMENT

CLINICAL PHARMACOLOGY
No bioequivalence studies have been performed and none are required for this application, as the product is administered as a parenteral aqueous solution, distributed rapidly in vivo.

EFFICACY
No new data has been provided.

SAFETY
No new data has been provided.

EXPERT REPORTS
The clinical expert report has been written by a suitably qualified person and is satisfactory.

PATIENT INFORMATION LEAFLET (PIL)
This is consistent with that for the reference product and is satisfactory.

LABELLING
These are satisfactory.

APPLICATION FORM (MAA)
This is satisfactory.

SUMMARY OF PRODUCT CHARACTERISTICS (SPC)
This is consistent with that for the reference product and is satisfactory.

DISCUSSION
A bioequivalence study with the reference product is not required for this product and can be justified as a generic medicinal product considering the quantitative and qualitative composition of the product and the route of administration.

MEDICAL CONCLUSION
The grant of a marketing authorisation is recommended for this application.
OVERALL CONCLUSION AND RISK BENEFIT ASSESSMENT

QUALITY
The important quality characteristics of Oxaliplatin 5mg/ml Powder for Solution for Infusion are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance.

PRECLINICAL
No new preclinical data were submitted and none are required for applications of this type.

EFFICACY
Oxaliplatin is a well-known drug and has been used for many years. Bioequivalence has been demonstrated between the applicant’s Oxaliplatin 5mg/ml Powder for Solution for Infusion and the reference product Eloxatin 5mg/ml Powder for Solution for Infusion (Sanofi-Synthelabo Limited).

No new or unexpected safety concerns arise from this application.

The SPC, PIL and labelling are satisfactory and consistent with those for the reference product Eloxatin 5mg/ml Powder for Solution for Infusion.

RISK BENEFIT ASSESSMENT
The quality of the product is acceptable and no new preclinical or clinical safety concerns have been identified. The data submitted supports the claim that the applicant’s product and the reference product are interchangeable. Extensive clinical experience with oxaliplatin is considered to have demonstrated the therapeutic value of the compound. The benefit/risk is, therefore, considered to be positive.
OXALIPLATIN 5MG/ML POWDER FOR SOLUTION FOR INFUSION
PL 18727/0010

STEPS TAKEN FOR ASSESSMENT

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The MHRA received the marketing authorisation application on 10th February 2007.</td>
</tr>
<tr>
<td>2</td>
<td>Following standard checks and communication with the applicant the MHRA considered the application valid on 13th March 2007.</td>
</tr>
<tr>
<td>4</td>
<td>The applicant responded to the MHRA’s requests, providing further information on 19th September 2007, 10th October 2007, 31st January 2008 and 24th November 2008 for the quality section. The applicant provided further information on 27th November 2007 and 31st January 2008 for the clinical section.</td>
</tr>
<tr>
<td>5</td>
<td>The application was determined on 25th February 2009.</td>
</tr>
</tbody>
</table>
OXALIPLATIN 5MG/ML POWDER FOR SOLUTION FOR INFUSION  
PL 18727/0010

STEPS TAKEN AFTER AUTHORISATION - SUMMARY

<table>
<thead>
<tr>
<th>Date submitted</th>
<th>Application type</th>
<th>Scope</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT
Oxaliplatin 5 mg/ml Powder for Solution for Infusion

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml of reconstituted solution contains oxaliplatin 5 mg. Each vial of 30 ml contains 50 mg and each vial of 50 ml contains 100 mg of oxaliplatin. Also contains Lactose Monohydrate. For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM
Powder for Solution for Infusion. White to off-white cake or powder.

4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:
Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumour. Treatment of metastatic colorectal cancer.

4.2 POSOLOGY AND METHOD OF ADMINISTRATION
FOR ADULTS ONLY
The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months). The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks. Dosage given should be adjusted according to tolerability (see section 4.4 “Special Warnings & Precautions for Use”).

Oxaliplatin should always be administered before fluoropyrimidines – i.e. 5-fluorouracil. Oxaliplatin is administered as a 2- to 6-hour intravenous infusion in 250 ml to 500 ml of 5% glucose solution to give a concentration between 0.2 mg/ml and 0.70 mg/ml; 0.70 mg/ml is the highest concentration in clinical practice for an oxaliplatin dose of 85 mg/m². Oxaliplatin was mainly used in combination with continuous infusion 5-fluorouracil based regimens. For the two-weekly treatment schedule 5-fluorouracil regimens combining bolus and continuous infusion were used.

Special Populations
- Renal impairment:
Oxaliplatin has not been studied in patients with severe renal impairment (see section 4.3). In patients with moderate renal impairment, treatment may be initiated at the normally recommended dose (see section 4.4). There is no need for dose adjustment in patients with mild renal dysfunction.

- Hepatic insufficiency:
Oxaliplatin has not been studied in patients with severe hepatic impairment. No increase in oxaliplatin acute toxicities was observed in the subset of patients with abnormal liver function tests at baseline. No specific dose adjustment for patients with abnormal liver function tests was performed during clinical development.

- Elderly patients:
No increase in severe toxicities was observed when oxaliplatin was used as a single agent or in combination with 5-fluorouracil in patients over the age of 65. In consequence no specific dose adaptation is required for elderly patients.
Method of administration
Oxaliplatin is administered by intravenous infusion.
The administration of oxaliplatin does not require hyperhydration.
Oxaliplatin diluted in 250 ml to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml must be infused via a central venous line or peripheral vein over 2 to 6 hours. Oxaliplatin infusion must always precede the administration of 5-fluorouracil.
In the event of extravasation, administration must be discontinued immediately.

Instructions for use:
Oxaliplatin must be diluted before use. Only 5% glucose diluent is to be used to dilute the concentrate for solution for infusion product (See Section 6.6 Special precautions for disposal and other handling).

4.3 CONTRAINDICATIONS
Oxaliplatin is contraindicated in patients who
- have a known history of hypersensitivity to oxaliplatin.
- are breast feeding.
- have myelosuppression prior to starting first course, as evidenced by baseline neutrophils <2x10^9/L and/or platelet count of <100x10^9/L.
- have a peripheral sensitive neuropathy with functional impairment prior to first course.
- have a severely impaired renal function (creatinine clearance less than 30 ml/min).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Oxaliplatin should only be used in specialised departments of oncology and should be administered under the supervision of an experienced oncologist.
Due to limited information on safety in patients with moderately impaired renal function, administration should only be considered after suitable appraisal of the benefit/risk for the patient. In this situation, renal function should be closely monitored and dose adjusted according to toxicity.
Patients with a history of allergic reaction to platinum compounds should be monitored for allergic symptoms. In case of an anaphylactic-like reaction to oxaliplatin, the infusion should be immediately discontinued and appropriate symptomatic treatment initiated. Oxaliplatin rechallenge is contraindicated.

In case of oxaliplatin extravasation, the infusion must be stopped immediately and usual local symptomatic treatment initiated.

Neurological toxicity of oxaliplatin should be carefully monitored, especially if co-administered with other medications with specific neurological toxicity. A neurological examination should be performed before each administration and periodically thereafter.

For patients who develop acute laryngopharyngeal dysaesthesia (see section 4.8), during or within the hours following the 2-hour infusion, the next oxaliplatin infusion should be administered over 6 hours.
If neurological symptoms (paraesthesia, dysaesthesia) occur, the following recommended oxaliplatin dosage adjustment should be based on the duration and severity of these symptoms:
- If symptoms last longer than seven days and are troublesome, the subsequent oxaliplatin dose should be reduced from 85 mg/m^2 to 65 mg/m^2 (metastatic setting) or 75 mg/m^2 (adjuvant setting).
- If paraesthesia without functional impairment persists until the next cycle, the subsequent oxaliplatin dose should be reduced from 85 mg/m^2 to 65 mg/m^2 (metastatic setting) or 75 mg/m^2 (adjuvant setting).
- If paraesthesia with functional impairment persists until the next cycle, oxaliplatin should be discontinued.
- If these symptoms improve following discontinuation of oxaliplatin therapy, resumption of therapy may be considered.

Patients should be informed of the possibility of persistent symptoms of peripheral sensory neuropathy after the end of the treatment. Localised moderate paraesthesias or paraesthesias that may interfere with functional activities can persist after up to 3 years following treatment cessation in the adjuvant setting.
Gastrointestinal toxicity, which manifests as nausea and vomiting, warrants prophylactic and/or therapeutic anti-emetic therapy (see section 4.8).

Dehydration, paralytic ileus, intestinal obstruction, hypokalemia, metabolic acidosis and renal impairment may be caused by severe diarrhoea/emesis particularly when combining oxaliplatin with 5-fluorouracil.

If haematological toxicity occurs (neutrophils <1.5x10^9/l or platelets <50x10^9/l), administration of the next course of therapy should be postponed until haematological values return to acceptable levels. A full blood count with white cell differential should be performed prior to start of therapy and before each subsequent course.

Patients must be adequately informed of the risk of diarrhoea/emesis, mucositis/stomatitis and neutropenia after oxaliplatin and 5-fluorouracil administration so that they can urgently contact their treating physician for appropriate management. If mucositis/stomatitis occurs with or without neutropenia, the next treatment should be delayed until recovery from mucositis/stomatitis to grade 1 or less and/or until the neutrophil count is ≥1.5 x 10^9/l.

For oxaliplatin combined with 5-fluorouracil (with or without folinic acid), the usual dose adjustments for 5-fluorouracil associated toxicities should apply.

If grade 4 diarrhoea, grade 3 to 4 neutropenia (neutrophils <1.0x10^9/l), grade 3 to 4 thrombocytopenia (platelets <50x10^9/l) occur, the dose of oxaliplatin should be reduced from 85 mg/m² to 65 mg/m² (metastatic setting) or 75 mg/m² (adjuvant setting), in addition to any 5-fluorouracil dose reductions required.

In the case of unexplained respiratory symptoms such as non-productive cough, dyspnoea, crackles or radiological pulmonary infiltrates, oxaliplatin should be discontinued until further pulmonary investigations exclude an interstitial lung disease (see section 4.8).

For use in pregnant women, see section 4.6. Genotoxic effects were observed with oxaliplatin in the preclinical studies. Therefore male patients treated with oxaliplatin are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because oxaliplatin may have an anti-fertility effect which could be irreversible.

Women should not become pregnant during treatment with oxaliplatin and should use an effective method of contraception (see section 4.6).

4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
In patients who have received a single dose of 85 mg/m² of oxaliplatin, immediately before administration of 5-fluorouracil, no change in the level of exposure to 5-fluorouracil has been observed.

In vitro, no significant displacement of oxaliplatin binding to plasma proteins has been observed with the following agents: erythromycin, salicylates, granisetron, paclitaxel, and sodium valproate.

4.6 PREGNANCY AND LACTATION
To date there is no available information on safety of use in pregnant women. In animal studies, reproductive toxicity was observed. Consequently, oxaliplatin is not recommended during pregnancy and in women of childbearing potential not using contraceptive measures.

The use of oxaliplatin should only be considered after suitably appraising the patient of the risk to the foetus and with the patient's consent. Appropriate contraceptive measures must be taken during and after cessation of therapy during 4 months for women and 6 months for men.

Excretion in breast milk has not been studied. Breast-feeding is contra-indicated during oxaliplatin therapy.

Oxaliplatin may have an anti-fertility effect (see section 4.4).

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
No studies on the effects on the ability to drive and use machines have been performed. However oxaliplatin treatment resulting in an increase risk of dizziness, nausea and vomiting, and other neurologic symptoms that affect gait and balance may lead to a minor or moderate influence on the ability to drive and use machines.
4.8 UNDESIRABLE EFFECTS
The most frequent adverse events of oxaliplatin in combination with 5-fluorouracil/folinic acid (5-FU/FA) were gastrointestinal (diarrhoea, nausea, vomiting and mucositis), haematological (neutropenia, thrombocytopenia) and neurological (acute and dose cumulative peripheral sensory neuropathy). Overall, these adverse events were more frequent and severe with oxaliplatin and 5-FU/FA combination than with 5-FU/FA alone.

The frequencies reported in the table below are derived from clinical trials in the metastatic and adjuvant settings (having included 416 and 1108 patients respectively in the oxaliplatin + 5-FU/FA treatment arms) and from post marketing experience.

Frequencies in this table are defined using the following convention: very common (>1/10) common (>1/100, ≤1/10), uncommon (>1/1000, ≤1/100), rare (>1/10000, ≤1/1000), very rare (≤1/10000) including isolated report.

Further details are given after the table.

<table>
<thead>
<tr>
<th>MedDRA Organ system classes</th>
<th>Very common</th>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations *</td>
<td>- Infection</td>
<td>- Rhinitis</td>
<td>- Upper respiratory tract infection</td>
<td>- Autoimmune thrombocytopenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Febrile neutropenia/ Neutropenic sepsis</td>
<td></td>
<td>- Haemolytic anaemia</td>
</tr>
<tr>
<td>Blood and the lymphatic system disorders*</td>
<td>- Anaemia</td>
<td>- Neutropenia</td>
<td>- Thrombocytopenia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Leucopenia</td>
<td>- Lymphopenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune system disorders*</td>
<td>- Allergy/allergic reaction+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>- Anorexia</td>
<td>- Glycaemia abnormalities</td>
<td>- Hypokalaemia</td>
<td>- Dehydration -Metabolic acidosis</td>
</tr>
<tr>
<td></td>
<td>- Natraemia abnormalities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>- Depression</td>
<td>- Insomnia</td>
<td></td>
<td>- Nervousness</td>
</tr>
<tr>
<td>Nervous system disorders*</td>
<td>- Peripheral sensory neuropathy</td>
<td>- Dizziness</td>
<td>- Motor neuritis - Meningism</td>
<td>- Dysarthria</td>
</tr>
<tr>
<td></td>
<td>- Sensory disturbance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td>- Conjunctivitis</td>
<td>- Visual disturbance</td>
<td></td>
<td>-Visual acuity reduced transiently - Visual field disturbances - Optic neuritis</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>- Epistaxis</td>
<td>- Haemorrhage</td>
<td></td>
<td>- Ototoxicity - Deafness</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td>Haematuria</td>
<td>Deep vein thrombosis</td>
<td>Pulmonary embolism</td>
<td>Rectal haemorrhage</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>------------</td>
<td>----------------------</td>
<td>--------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>Hiccups</td>
<td>Chest pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Gastrointestinal disorders</strong></th>
<th>Interstitial lung disease</th>
<th>Pulmonary fibrosis**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>- Dyspepsia</td>
<td>- Ileus</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>- Gastroesophageal reflux</td>
<td>- Intestinal obstruction</td>
</tr>
<tr>
<td>Vomiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomatitis/ Mucositis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Skin and subcutaneous tissue disorders</strong></th>
<th>Interstitial lung disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin disorder</td>
<td>Colitis</td>
</tr>
<tr>
<td>Alopecia</td>
<td></td>
</tr>
<tr>
<td>Skin exfoliation (i.e. Hand &amp; Foot syndrome)</td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td></td>
</tr>
<tr>
<td>Rash erythematous</td>
<td></td>
</tr>
<tr>
<td>Rash Hyperhidrosis</td>
<td></td>
</tr>
<tr>
<td>Nail disorder</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Musculoskeletal, connective tissue and bone disorders</strong></th>
<th>Interstitial lung disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Back pain</td>
<td>Colitis</td>
</tr>
<tr>
<td>Arthralgia</td>
<td></td>
</tr>
<tr>
<td>Bone pain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Renal and urinary disorders</strong></th>
<th>Interstitial lung disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysuria</td>
<td>Colitis</td>
</tr>
<tr>
<td>Micturition frequency abnormal</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>General disorders and administration site conditions</strong></th>
<th>Interstitial lung disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>Colitis</td>
</tr>
<tr>
<td>Fever++</td>
<td></td>
</tr>
<tr>
<td>Asthenia</td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td></td>
</tr>
<tr>
<td>Injection site reaction+++</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Investigations</strong></th>
<th>Interstitial lung disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic enzyme increase</td>
<td>Colitis</td>
</tr>
<tr>
<td>Blood alkaline phosphatase increase</td>
<td></td>
</tr>
<tr>
<td>Blood bilirubin increase</td>
<td></td>
</tr>
<tr>
<td>Blood lactate dehydrogenase increase</td>
<td></td>
</tr>
<tr>
<td>Weight increase (adjuvant setting)</td>
<td></td>
</tr>
<tr>
<td>Blood creatinine increase</td>
<td></td>
</tr>
<tr>
<td>Weight decrease (metastatic setting)</td>
<td></td>
</tr>
</tbody>
</table>

* See detailed section below

** See section 4.4.

+ Common allergic reactions such as skin rash (particularly urticaria), conjunctivitis, rhinitis.

Common anaphylactic reactions, including bronchospasm, angioedema, hypotension and anaphylactic shock.

++ Very common fever, either from infection (with or without febrile neutropenia) or isolated fever from immunological mechanism.

+++ Extravasation may result in local pain and inflammation which may be severe and lead to complications, especially when oxaliplatin is infused through a peripheral vein (see 4.4).
Haematological toxicity:
Incidence by patient (%), by grade

<table>
<thead>
<tr>
<th>Oxaliplatin and 5-FU/FA 85 mg/m²</th>
<th>Metastatic Setting</th>
<th>Adjuvant Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>every 2 weeks</td>
<td>All grades</td>
<td>Gr 3</td>
</tr>
<tr>
<td>Anemia</td>
<td>82.2</td>
<td>3</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>71.4</td>
<td>28</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>71.6</td>
<td>4</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>5.0</td>
<td>3.6</td>
</tr>
<tr>
<td>Neutropenic sepsis</td>
<td>1.1</td>
<td>0.7</td>
</tr>
</tbody>
</table>

Digestive toxicity:
Incidence by patient (%), by grade

<table>
<thead>
<tr>
<th>Oxaliplatin and 5-FU/FA 85 mg/m²</th>
<th>Metastatic Setting</th>
<th>Adjuvant Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>every 2 weeks</td>
<td>All grades</td>
<td>Gr 3</td>
</tr>
<tr>
<td>Nausea</td>
<td>69.9</td>
<td>8</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>60.8</td>
<td>9</td>
</tr>
<tr>
<td>Vomiting</td>
<td>49.0</td>
<td>6</td>
</tr>
<tr>
<td>Mucositis/Stomatitis</td>
<td>39.9</td>
<td>4</td>
</tr>
</tbody>
</table>

Prophylaxis and/or treatment with potent antiemetic agents is indicated.
Dehydration, paralytic ileus, intestinal obstruction, hypokalemia, metabolic acidosis and renal impairment may be caused by severe diarrhoea/emesis particularly when combining oxaliplatin with 5-fluorouracil (see section 4.4).

Nervous system:
The dose limiting toxicity of oxaliplatin is neurological. It involves a sensory peripheral neuropathy characterised by dysesthesia and/or paraesthesia of the extremities with or without cramps, often triggered by the cold. These symptoms occur in up to 95% of patients treated. The duration of these symptoms, which usually regress between courses of treatment, increases with the number of treatment cycles.

The onset of pain and/or a functional disorder are indications, depending on the duration of the symptoms, for dose adjustment, or even treatment discontinuation (see section 4.4). This functional disorder includes difficulties in executing delicate movements and is a possible consequence of sensory impairment. The risk of occurrence of persistent symptoms for a cumulative dose of 850 mg/m² (10 cycles) is approximately 10% and 20% for a cumulative dose of 1020 mg/m² (12 cycles).

In the majority of the cases, the neurological signs and symptoms improve or totally recover when treatment is discontinued. In the adjuvant setting of colon cancer, 6 months after treatment cessation, 87% of patients had no or mild symptoms. After up to 3 years of follow up, about 3% of patients presented either with persisting localised paraesthesias of moderate intensity (2.3%) or with paraesthesias that may interfere with functional activities (0.5%).

Acute neurosensory manifestations (see section 5.3) have been reported. They start within hours of administration and often occur on exposure to cold. They may present as transient paraesthesia, dysesthesia and hypoesthesia or as an acute syndrome of pharyngolaryngeal dysesthesia. This acute syndrome of pharyngolaryngeal dysesthesia, with an incidence estimated between 1% and 2%, is characterised by subjective sensations of dysphagia or dyspnoea, without any objective evidence of respiratory distress (no cyanosis or hypoxia) or of laryngospasm or bronchospasm (no stridor or wheezing); jaw spasm, abnormal tongue sensation, dysarthria and a feeling of chest pressure have also been observed. Although antihistamines and bronchodilators have been administered in such cases, the symptoms are rapidly reversible even in the absence of treatment. Prolongation of the infusion helps to reduce the incidence of this syndrome (see section 4.4).
Other neurological symptoms such as dysarthria, loss of deep tendon reflex and Lhermitte's sign were reported during treatment with oxaliplatin. Isolated cases of optic neuritis have been reported.

**Allergic reactions:**

<table>
<thead>
<tr>
<th>Incidence by patient (%)</th>
<th>Metastatic Setting</th>
<th>Adjuvant Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All grades</td>
<td>Gr 3</td>
</tr>
<tr>
<td>Allergic reactions / Allergy</td>
<td>9.1</td>
<td>1</td>
</tr>
</tbody>
</table>

4.9 **OVERDOSE**

There is no known antidote to oxaliplatin. In cases of overdose, exacerbation of adverse events can be expected. Monitoring of haematological parameters should be initiated and symptomatic treatment given.

5 **PHARMACOLOGICAL PROPERTIES**

5.1 **PHARMACODYNAMIC PROPERTIES**

Pharmacotherapeutic group: Antineoplastic Agents, Other Antineoplastic Agents: Platinum Compounds
ATC code: L01XA 03

Oxaliplatin is an antineoplastic drug belonging to a new class of platinum-based compounds in which the platinum atom is complexed with 1,2-diaminocyclohexane ("DACH") and an oxalate group. Oxaliplatin is a single enantiomer, \((S^P,P^-4,2)-[(1R,2R)-Cyclohexane-1,2-diamine-kN,kN']\) \([\text{ethanedioato(2-)-kO}_1,kO_2]\) platinum.

Oxaliplatin exhibits a wide spectrum of both *in vitro* cytotoxicity and *in vivo* antitumour activity in a variety of tumour model systems including human colorectal cancer models. Oxaliplatin also demonstrates *in vitro* and *in vivo* activity in various cisplatin resistant models. A synergistic cytotoxic action has been observed in combination with 5-fluorouracil both *in vitro* and *in vivo*.

Studies on the mechanism of action of oxaliplatin, although not completely elucidated, show that the aqua-derivatives resulting from the biotransformation of oxaliplatin, interact with DNA to form both inter and intra-strand cross-links, resulting in the disruption of DNA synthesis leading to cytotoxic and antitumour effects.

In patients with metastatic colorectal cancer, the efficacy of oxaliplatin (85 mg/m² repeated every two weeks) combined with 5-fluorouracil/folinic acid (5-FU/FA) is reported in three clinical studies:

- In front-line treatment, the 2-arm comparative phase III EFC2962 study randomised 420 patients either to 5-FU/FA alone (LV5FU2, N=210) or the combination of oxaliplatin with 5-FU/FA (FOLFOX4, N=210)

- In pretreated patients, the comparative three arms phase III study EFC4584 randomised 821 patients refractory to 5-FU/FA alone (LV5FU2, N=275), oxaliplatin single agent (N=275), or combination of oxaliplatin with 5-FU/FA (FOLFOX4, N=271).

- Finally, the uncontrolled phase II EFC2964 study included patients refractory to 5-FU/FA alone, that were treated with the oxaliplatin and 5-FU/FA combination (FOLFOX4, N=57)

The two randomised clinical trials, EFC2962 in front-line therapy and EFC4584 in pretreated patients, demonstrated a significantly higher response rate and a prolonged progression free survival (PFS)/time to progression (TTP) as compared to treatment with 5-FU/FA alone. In EFC4584 performed in refractory pretreated patients, the difference in median overall survival (OS) between the combination of oxaliplatin and 5-FU/FA did not reach statistical significance.
Response rate under FOLFOX4 versus LV5FU2

<table>
<thead>
<tr>
<th>Response rate, % (95% CI) independent radiological review ITT analysis</th>
<th>LV5FU2</th>
<th>FOLFOX4</th>
<th>Oxaliplatin Single agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Front-line treatment EFC2962</td>
<td>22 (16-27)</td>
<td>49 (42-46)</td>
<td>NA*</td>
</tr>
<tr>
<td>Response assessment every 8 weeks</td>
<td>P value = 0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreated patients EFC4584 (refractory to CPT-11 + 5-FU/FA)</td>
<td>0.7 (0.0-2.7)</td>
<td>11.1 (7.6-15.5)</td>
<td>1.1 (0.2-3.2)</td>
</tr>
<tr>
<td>Response assessment every 6 weeks</td>
<td>P value &lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreated patients EFC2964 (refractory to 5-FU/FA) Response assessment every 12 weeks</td>
<td>NA*</td>
<td>23 (13-36)</td>
<td>NA*</td>
</tr>
</tbody>
</table>

* NA: Not Applicable

Median Progression Free Survival (PFS) / Median Time to Progression (TTP)

FOLFOX4 versus LV5FU2

<table>
<thead>
<tr>
<th>Median PFS/TTP, Months (95% CI) independent radiological review ITT analysis</th>
<th>LV5FU2</th>
<th>FOLFOX4</th>
<th>Oxaliplatin Single agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Front-line treatment EFC2962 (PFS)</td>
<td>6.0 (5.5-6.5)</td>
<td>8.2 (7.2-8.8)</td>
<td>NA*</td>
</tr>
<tr>
<td>Log-rank P value = 0.0003</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreated patients EFC4584 (TTP) (refractory to CPT-11 + 5-FU/FA)</td>
<td>2.6 (1.8-2.9)</td>
<td>5.3 (4.7-6.1)</td>
<td>2.1 (1.6-2.7)</td>
</tr>
<tr>
<td>Log-rank P value &lt;0.0001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreated patients EFC2964 (refractory to 5-FU/FA)</td>
<td>NA*</td>
<td>5.1 (3.1-5.7)</td>
<td>NA*</td>
</tr>
</tbody>
</table>

* NA: Not Applicable

Median Overall Survival (OS) under FOLFOX4 versus LV5FU2

<table>
<thead>
<tr>
<th>Median OS, months (95% CI) ITT analysis</th>
<th>LV5FU2</th>
<th>FOLFOX4</th>
<th>Oxaliplatin Single agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Front-line treatment EFC2962</td>
<td>14.7 (13.0-18.2)</td>
<td>16.2 (14.7-18.2)</td>
<td>NA*</td>
</tr>
<tr>
<td>Log-rank P value = 0.12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreated patients EFC4584 (refractory to CPT-11 + 5-FU/FA)</td>
<td>8.8 (7.3 - 9.3)</td>
<td>9.9 (9.1-10.5)</td>
<td>8.1 (7.2-8.7)</td>
</tr>
<tr>
<td>Log-rank P value = 0.09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreated patients EFC2964 (refractory to 5-FU/FA)</td>
<td>NA*</td>
<td>10.8 (9.3-12.8)</td>
<td>NA*</td>
</tr>
</tbody>
</table>

*NA: Not Applicable

In pretreated patients (EFC4584), who were symptomatic at baseline, a higher proportion of those treated with oxaliplatin and 5-FU/FA experienced a significant improvement of their disease-related symptoms compared to those treated with 5-FU/FA alone (27.7% vs 14.6% p = 0.0033).

In non-pretreated patients (EFC2962), no statistically significant difference between the two treatment groups was found for any of the quality of life dimensions. However, the quality of life scores were generally better in the control arm for measurement of global health status and pain and worse in the oxaliplatin arm for nausea and vomiting.

In the adjuvant setting, the MOSAIC comparative phase III study (EFC3313) randomised 2246 patients (899 stage II/Duke's B2 and 1347 stage III/Duke's C) further to complete resection of the primary tumour of colon cancer either to 5-FU/FA alone (LV5FU2, N=1123 (B2/C = 448/675) or to combination of oxaliplatin and 5-FU/FA (FOLFOX4, N=1123 (B2/C) = 451/672).
EFC 3313 3-year disease free survival (ITT analysis)* for the overall population.

<table>
<thead>
<tr>
<th>Treatment arm</th>
<th>LV5FU2</th>
<th>FOLFOX4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent 3-year disease free survival (95% CI)</td>
<td>73.3 (70.6-75.9)</td>
<td>78.7 (76.2-81.1)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.76 (0.64-0.89)</td>
<td></td>
</tr>
<tr>
<td>Stratified log rank test</td>
<td>P=0.0008</td>
<td></td>
</tr>
</tbody>
</table>

* median follow up 44.2 months (all patients followed for at least 3 years)

The study demonstrated an overall significant advantage in 3-year disease free survival for the oxaliplatin and 5-FU/FA combination (FOLFOX4) over 5-FU/FA alone (LV5FU2).

EFC 3313 3-year Disease Free Survival (ITT analysis)* according to Stage of disease

<table>
<thead>
<tr>
<th>Patient stage</th>
<th>Stage II (Duke's B2)</th>
<th>Stage III (Duke's C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment arm</td>
<td>LV5FU2</td>
<td>FOLFOX4</td>
</tr>
<tr>
<td>Percent 3-year disease free survival (95% CI)</td>
<td>84.3 (80.9-87.7)</td>
<td>87.4 (84.3-90.5)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.79 (0.57-1.09)</td>
<td>0.75 (0.62-0.90)</td>
</tr>
<tr>
<td>Log-rank test</td>
<td>P=0.151</td>
<td>P=0.002</td>
</tr>
</tbody>
</table>

* median follow up 44.2 months (all patients followed for at least 3 years)

Overall Survival (ITT analysis):

At time of the analysis of the 3-year disease free survival, which was the primary endpoint of the MOSAIC trial, 85.1% of the patients were still alive in the FOLFOX4 arm versus 83.8% in the LV5FU2 arm. This translated into an overall reduction in mortality risk of 10% in favour of FOLFOX4 not reaching statistical significance (hazard ratio = 0.90). The figures were 92.2% versus 92.4% in the stage II (Duke's B2) sub-population (hazard ratio = 1.01) and 80.4% versus 78.1% in the stage III (Duke's C) sub-population (hazard ratio = 0.87), for FOLFOX4 and LV5FU2, respectively.

5.2 PHARMACOKINETIC PROPERTIES

The pharmacokinetics of individual active compounds have not been determined. The pharmacokinetics of ultrafiltrable platinum, representing a mixture of all unbound, active and inactive platinum species, following a two-hour infusion of oxaliplatin at 130 mg/m² every three weeks for 1 to 5 cycles and oxaliplatin at 85 mg/m² every two weeks for 1 to 3 cycles are as follows:

**Summary of Platinum Pharmacokinetic Parameter Estimates in Ultrafiltrate Following Multiple Doses of Oxaliplatin at 85 mg/m² Every Two Weeks or at 130 mg/m² Every Three Weeks**

<table>
<thead>
<tr>
<th>Dose</th>
<th>Cmax</th>
<th>AUC0-48</th>
<th>AUC</th>
<th>t1/2α</th>
<th>t1/2β</th>
<th>t1/2γ</th>
<th>Vss</th>
<th>CL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>μg/mL</td>
<td>μg·h/mL</td>
<td>μg·h/mL</td>
<td>h</td>
<td>h</td>
<td>h</td>
<td>L</td>
<td>L/h</td>
</tr>
<tr>
<td>85 mg/m² Mean</td>
<td>0.814</td>
<td>4.19</td>
<td>4.68</td>
<td>0.43</td>
<td>16.8</td>
<td>391</td>
<td>440</td>
<td>17.4</td>
</tr>
<tr>
<td>SD</td>
<td>0.193</td>
<td>0.647</td>
<td>1.40</td>
<td>0.35</td>
<td>5.74</td>
<td>406</td>
<td>199</td>
<td>6.35</td>
</tr>
<tr>
<td>130 mg/m² Mean</td>
<td>1.21</td>
<td>8.20</td>
<td>11.9</td>
<td>0.28</td>
<td>16.3</td>
<td>273</td>
<td>582</td>
<td>10.1</td>
</tr>
<tr>
<td>SD</td>
<td>0.10</td>
<td>2.40</td>
<td>4.60</td>
<td>0.06</td>
<td>2.90</td>
<td>19.0</td>
<td>261</td>
<td>3.07</td>
</tr>
</tbody>
</table>

Mean AUC0-48, and Cmax values were determined on Cycle 3 (85 mg/m²) or cycle 5 (130 mg/m²).

Mean AUC, Vss, CL, and CL1/0-48 values were determined on Cycle 1.

Cmax, AUC, AUC0-48, Vss, and CL values were determined by non-compartmental analysis. t1/2α, t1/2β, and t1/2γ, were determined by compartmental analysis (Cycles 1 to 3 combined).

At the end of a 2-hour infusion, 15% of the administered platinum is present in the systemic circulation, the remaining 85% being rapidly distributed into tissues or eliminated in the urine. Irreversible binding to red blood cells and plasma, results in half-lives in these matrices that are close to the natural turnover of red blood cells and serum albumin. No accumulation was observed in plasma ultrafiltrate following 85 mg/m² every two weeks or 130mg/m² every three weeks and steady state was attained by cycle one in this matrix. Inter- and intra-subject variability is generally low.
Biotransformation *in vitro* is considered to be the result of non-enzymatic degradation and there is no evidence of cytochrome P450-mediated metabolism of the diaminocyclohexane (DACH) ring. Oxaliplatin undergoes extensive biotransformation in patients, and no intact drug was detectable in plasma ultrafiltrate at the end of a 2h-infusion. Several cytotoxic biotransformation products including the monochloro-, dichloro- and diaquo-DACH platinum species have been identified in the systemic circulation together with a number of inactive conjugates at later time points. Platinum is predominantly excreted in urine, with clearance mainly in the 48 hours following administration.

By day 5, approximately 54% of the total dose was recovered in the urine and <3% in the faeces. A significant decrease in clearance from 17.6 ± 2.18 l/h to 9.95 ± 1.91 l/h in renal impairment was observed together with a statistically significant decrease in distribution volume from 330 ± 40.9 to 241 ± 36.1 l. The effect of severe renal impairment on platinum clearance has not been evaluated.

5.3 PRECLINICAL SAFETY DATA
The target organs identified in preclinical species (mice, rats, dogs, and/or monkeys) in single- and multiple-dose studies included the bone marrow, the gastrointestinal system, the kidney, the testes, the nervous system, and the heart. The target organ toxicities observed in animals are consistent with those produced by other platinum-containing drugs and DNA-damaging, cytotoxic drugs used in the treatment of human cancers with the exception of the effects produced on the heart. Effects on the heart were observed only in the dog and included electrophysiological disturbances with lethal ventricular fibrillation. Cardiotoxicity is considered specific to the dog not only because it was observed in the dog alone but also because doses similar to those producing lethal cardiotoxicity in dogs (150 mg/m²) were well-tolerated by humans. Preclinical studies using rat sensory neurons suggest that the acute neurosensory symptoms related to Oxaliplatin may involve an interaction with voltage-gated Na⁺ channels.

Oxaliplatin was mutagenic and clastogenic in mammalian test systems and produced embryo-fetal toxicity in rats. Oxaliplatin is considered a probable carcinogen, although carcinogenic studies have not been conducted.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS
Lactose monohydrate.

6.2 INCOMPATIBILITIES
The diluted medicinal product should not be mixed with other medications in the same infusion bag or infusion line. Under instructions for use described in section 6.6, oxaliplatin can be co-administered with folinic acid via a Y-line.

- DO NOT mix with alkaline drugs or solutions, in particular 5-fluorouracil, folinic acid preparations containing trometamol as an excipient and trometamol salts of other drugs. Alkaline drugs or solutions will adversely affect the stability of oxaliplatin (see section 6.6).

- DO NOT reconstitute oxaliplatin with saline or other solutions containing chloride ions (including calcium, potassium or sodium chlorides).

- DO NOT mix with other drugs in the same infusion bag or infusion line (see section 6.6 for instructions concerning simultaneous administration with folinic acid).

- DO NOT use injection equipment containing aluminium. This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 SHELF LIFE
Medicinal product as packaged for sale: 2 years
Reconstituted solution in the original vial:
From a microbiological and chemical point of view, the reconstituted solution should be diluted immediately.
Infusion preparation:
Chemical and physical in-use stability has been demonstrated for 20 °C to 25 °C up to 6 hours and 24 hours at 2 °C to 8 °C. From a microbiological point of view, the infusion preparation should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 20 °C to 25 °C up to 6 hours and 24 hours at 2 °C to 8 °C unless dilution has taken place in controlled and validated aseptic conditions.

6.4 SPECIAL PRECAUTIONS FOR STORAGE
Medicinal product as packaged for sale: No special storage conditions are required.
Reconstituted solution: should be diluted immediately.
Infusion preparation: store at 20 °C to 25 °C up to 6 hours and 2 °C to 8 °C for not longer than 24 hours.
Inspect visually prior to use. Only clear solutions without particles should be used.
The medicinal product is for single use only. Any unused solution should be discarded.
For storage conditions of the reconstituted medicinal product, see section 6.3.

6.5 NATURE AND CONTENTS OF CONTAINER
30 ml type-I, clear, colourless glass vial with Lyotec rubber stopper, containing 50 mg of oxaliplatin.
50 ml type-I, clear, colourless glass vial with Lyotec rubber stopper, containing 100 mg of oxaliplatin.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL
As with other potentially toxic compounds, caution should be exercised when handling and preparing oxaliplatin solutions.

Instructions for Handling
The handling of this cytotoxic agent by nursing or medical personnel requires every precaution to guarantee the protection of the handler and his surroundings.
The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicines used, in conditions that guarantee the integrity of the product, the protection of the environment and in particular the protection of the personnel handling the medicines, in accordance with the hospital policy. It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area.
Personnel must be provided with appropriate handling materials, notably long sleeved gowns, protection masks, caps, protective goggles, sterile single-use gloves, protective covers for the work area, containers and collection bags for waste.
Excreta and vomit must be handled with care.
Pregnant women must be warned to avoid handling cytotoxic agents.
Any broken container must be treated with the same precautions and considered as contaminated waste. Contaminated waste should be incinerated in suitably labelled rigid containers. See below section “Disposal”.

If oxaliplatin concentrate, reconstituted solution or infusion solution should come into contact with skin, wash immediately and thoroughly with water.
If oxaliplatin concentrate, premix solution or infusion solution should come into contact with mucous membranes, wash immediately and thoroughly with water.

Special precautions for administration
- DO NOT use injection material containing aluminium.
- DO NOT administer undiluted.
- Do not reconstitute or dilute for infusion with saline solution.
- DO NOT mix with any other medication in the same infusion bag or administer simultaneously by the same infusion line (in particular 5-fluorouracil, basic solutions, trometamol and folinic acid products containing trometamol as an excipient).
Oxaliplatin can be co-administered with folinic acid infusion using a Y-line placed immediately before the site of injection. The drugs should not be combined in the same infusion bag. Folinic acid must be diluted using isotonic infusion solutions such as 5% glucose solution but NOT sodium chloride solutions or alkaline solutions.
Flush the line after oxaliplatin administration.
- USE ONLY the recommended solvents (see below).
- Any reconstituted solution that shows evidence of precipitation should not be used and should be destroyed with due regard to legal requirements for disposal of hazardous waste (see below).

Reconstitution of the solution
- Water for injections or 5% glucose solution should be used to reconstitute the solution.
- For a vial of 50 mg: add 10 ml of solvent to obtain a concentration of 5 mg oxaliplatin/ml.
- For a vial of 100 mg: add 20 ml of solvent to obtain a concentration of 5 mg oxaliplatin/ml.

From a microbiological and chemical point of view, the reconstituted solution should be diluted immediately with 5% glucose solution.
Inspect visually prior to use. Only clear solutions without particles should be used.
The medicinal product is for single use only. Any unused solution should be discarded.

Dilution before infusion
Withdraw the required amount of reconstituted solution from the vial(s) and then dilute with 250 ml to 500 ml of a 5% glucose solution to give an oxaliplatin concentration between not less than 0.2 mg/ml and not more than 0.6 mg/ml.

Administer by I.V. infusion.
Chemical and physical in-use stability has been demonstrated for 20 °C to 25 °C up to 6 hours and 24 hours at 2 °C to 8 °C.
From a microbiological point of view, this infusion preparation should be used immediately.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 6 hours at 20 °C to 25 °C and 24 hours at 2 °C to 8 °C or unless dilution has taken place in controlled and validated aseptic conditions.
Inspect visually prior to use. Only clear solutions without particles should be used.
The medicinal product is for single use only. Any unused solution should be discarded.
NEVER use sodium chloride solution for either reconstitution or dilution.

Infusion
The administration of oxaliplatin does not require prehydration.
Oxaliplatin diluted in 250 ml to 500 ml of a 5% glucose solution to give a concentration not less than 0.2 mg/ml must be infused either by peripheral vein or central venous line over 2 to 6 hours. When oxaliplatin is administered with 5-fluorouracil, the oxaliplatin infusion should precede that of 5-fluorouracil.

Disposal
Remnants of the medicinal product as well as all materials that have been used for reconstitution, for dilution and administration must be destroyed according to hospital standard procedures applicable to cytotoxic agents with due regard to current laws related to the disposal of hazardous waste.

7 MARKETING AUTHORISATION HOLDER
Fresenius Kabi Oncology Plc.
Lion Court, Farnham Road
Bordon, Hampshire GU35 0NF,
United Kingdom.

8 MARKETING AUTHORISATION NUMBER(S)
PL 18727/0010

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
25/02/2009

10 DATE OF REVISION OF THE TEXT
25/02/2009
11 DOSIMETRY (IF APPLICABLE)

12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)
PACKAGE LEAFLET: INFORMATION FOR THE USER
OXALIPLATIN 5 MG/ML
POWDER FOR SOLUTION FOR INFUSION
(OXALIPLATIN)

Read all of this leaflet carefully before you are given Oxaliplatin
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:
1. What Oxaliplatin is and what it is used for
2. Before you are given Oxaliplatin
3. How Oxaliplatin is given
4. Possible side effects
5. How to store Oxaliplatin
6. Further information

1. WHAT OXALIPLATIN IS AND WHAT IT IS USED FOR
Oxaliplatin is an antineoplastic or anticancer drug, which has platinum in its chemical structure.
It is used to treat cancer of the large bowel (colon and rectum). Oxaliplatin is used in combination with other anticancer medicines called 5-fluorouracil (5-FU) and leucovorin (folinic acid).

2. BEFORE YOU ARE GIVEN OXALIPLATIN
You should not be given Oxaliplatin if you:
• have a known allergy to Oxaliplatin or any of the other ingredients of Oxaliplatin, lactose monohydrate,
• are breast-feeding,
• already have a reduced number of red or white blood cells,
• already have tingling and numbness in the fingers and/or toes, and have difficulty performing delicate tasks, such as buttoning clothes,
• have severe kidney problems.
Take special care with Oxaliplatin if you:
• have ever suffered an allergic reaction to platinum-containing medicines such as carboplatin, cisplatin.
• have moderate kidney problems.

Taking other medicines:
Please inform your doctor or pharmacist if you are taking, or have recently taken, any other medicine - even those not prescribed.

Pregnancy and breast-feeding:
If you are pregnant or planning a pregnancy it is very important that you discuss this with your doctor before you receive any treatment.
Ask your doctor or pharmacist for advice before taking any medicine.
You must not become pregnant during treatment with oxaliplatin and must use an effective method of contraception. If pregnancy occurs during your treatment, you must immediately inform your doctor. You should take appropriate contraceptive measures during and after cessation of therapy, during 4 months for women and 6 months for men.
Oxaliplatin may have an anti-fertility effect, which could be irreversible. Male patients are therefore advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment.
You should not be given Oxaliplatin if you are breast-feeding.

Driving and using machines:
Since, oxaliplatin treatment may result in an increase risk of dizziness, nausea and vomiting, and other neurological symptoms that affect gait and balance, it may lead to a minor or moderate influence on your ability to drive and use machines.

3. HOW OXALIPLATIN IS GIVEN
Oxaliplatin will be prescribed for you by a specialist in cancer treatment.
Oxaliplatin is given by injection into a vein (an intravenous infusion) over 2 to 6 hour period. The injection is made by mixing the powder with water for injections or 5% glucose solution. About 250 ml of the glucose solution is usually used.
Oxaliplatin will be made up in a special area before the doctor or nurse gives it to you.
The dose of Oxaliplatin is based on your body surface area. This is calculated from your height and weight.
The usual dose for adults including the elderly is 85 mg/m² of body surface area once every 2 weeks before the infusion of the other anticancer medicines.
The dose you receive will also depend on results of blood tests and whether you have previously experienced side effects with Oxaliplatin. The needle must remain in the vein while the drug is being given. If the needle comes out or becomes loose, or the solution is going into the tissue outside the vein (you may feel discomfort or pain) - tell the doctor or nurse immediately.
If you are given more Oxaliplatin than you should:
As this medicine is given in a hospital, it is unlikely that you will be given too little or too much, however tell your doctor if you have any concerns.
An overdose of this medicine may be dangerous. Your doctor will ensure that the correct dose for your condition is given.

4. POSSIBLE SIDE EFFECTS
Like all medicines, Oxaliplatin can cause side effects although not everybody gets them. If you experience any side effect it is important that you inform your doctor before your next treatment.
Tell your doctor immediately if you notice any of the following:
• Abnormal bruising, bleeding or signs of infection such as a sore throat and high temperature.
• Persistent or severe diarrhoea or vomiting.
• Stomatitis/mucositis ( sore lips or mouth ulcers).
• Unexplained respiratory symptoms such as a non-productive cough, difficulty in breathing or crackles.
• Symptoms of angioedema - swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing).
The most common side effects (in more than 10% of patients) are:
• A disorder of the nerves which can cause weakness, tingling or numbness in fingers, toes, around the mouth or in the throat that may sometimes occur in association with cramps. This is often triggered by exposure to cold, e.g. opening a refrigerator or holding a cold drink. You may also have difficulty in performing delicate tasks, such as buttoning clothes. Although in the majority of cases these symptoms resolve completely, there is a possibility of persistent symptoms after the end of the treatment.
Some people have experienced a tingling shock-like sensation passing down the arms or trunk when the neck is flexed.
Oxaliplatin can sometimes cause an unpleasant sensation in the throat, in particular when swallowing, and give the sensation of shortness of breath. This sensation, if it happens, usually occurs during or within hours of the infusion and may be triggered by exposure to the cold. Although unpleasant, it will not last long and goes away without the need for any treatment. Your doctor may decide to alter your treatment as a result.
Signs of infection such as a sore throat and high temperature.
Reduction in the number of white blood cells, which may make you more prone to infections.
Reduction in blood platelets, which increases the risk of bleeding or bruising.
Reduction in red blood cells, which can make the skin pale and cause weakness or breathlessness. Your doctor will take blood to check that you have sufficient blood cells before you start treatment and before each subsequent cycle.
Allergic reactions - skin rash including red itchy skin, swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing) and you may feel you are going to faint.
Loss or lack of appetite.
Too high levels of glucose (sugar) in your blood which may cause a great thirst, dry mouth or a need to urinate more often.
Low blood levels of potassium which can cause abnormal heart rhythm.
Low blood levels of sodium which can cause tiredness and confusion, muscle twitching, fits or coma.
Taste disorder.
Headache.
Nosebleeds.
Shortness of breath.
Coughing.
Nausea (feeling sick), vomiting (being sick) - medication to prevent sickness is usually given to you by your doctor before treatment and maybe continued after treatment.
Diarrhoea, if you suffer from persistent or severe diarrhoea or vomiting, contact your doctor immediately for advice.
Sore mouth or lips, mouth ulcers.
Stomach pain, constipation.
Skin disorder.
Hair loss.
Back pain.
Tiredness, loss of strength/weakness, body pain.
Pain or redness close to or at the injection site during the infusion.
Fever.
Blood tests which show changes in the way the liver is working.

Common side effects (in 1% to 10% of patients) are:
- Runny nose.
- Chest infection.
- Dehydration.
- Excessive excitability or irritability.
- Dizziness.
- Swelling of the nerves to your muscles.
- Neck stiffness, intolerance/dislike of bright light and headache.
- Conjunctivitis, visual problems.
- Abnormal bleeding, blood in the urine and stools.
- Blood clot, usually in a leg, which causes pain swelling or redness.
- Blood clot in the lungs which causes chest pain and breathlessness.
- Flushing.
- Chest pain, hiccups.
- Indigestion and heartburn.
- Flaking skin, skin rash, increased sweating and nail disorder.
- Joint pain and bone pain.
- Pain on passing urine or a change in frequency when passing urine.
- Blood tests which show changes in the way the kidney is working.
- Loss of weight.
- Depression.
- Difficulty sleeping.

Uncommon side effects (in 0.1% to 1% of patients) are:
- Hearing problems.
- Blockage or swelling of the bowel.
- Feeling anxious or nervous.
- Blood tests which show an increase in acidity.

Rare side effects (in 0.01% to 0.1% of patients) are:
- Slurred speech.
- Deafness.
- Unexplained respiratory symptoms, difficulties in breathing, scarring of the lungs which causes shortness of breath.
- Inflammation which causes abdominal pain or diarrhoea.

Very rare effects (less than 1 in 10,000 patient) are:
- Liver disease that your doctor will monitor you for.
- Changes in kidney function.
If any of the side effects get serious or, if you notice any side effects not mentioned in this leaflet, please inform your doctor.

5. HOW TO STORE OXALIPLATIN

Keep out of the reach and sight of children.

Expiry Date
Do not use this medicine after the last day of the month shown on the pack.

Storing your medicine
No special storage conditions are required. The reconstituted solution should be diluted immediately in water for injections or glucose 5% solution to give a concentration between not less than 0.2 mg/ml and 0.6 mg/ml. Once diluted in 5% glucose solution, the infusion preparation should be used immediately. Chemical and physical in-use stability has been demonstrated for 6 hours at 20 °C to 25 °C and 24 hours at 2 °C to 8 °C. If not used immediately, in-use storage times and conditions are the responsibility of the user and would not normally be longer than 6 hours at 20 °C to 25 °C and 24 hours at 2 °C to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions. When the infusion has finished, Oxaliplatin will be disposed of carefully by the doctor or nurse.

5. FURTHER INFORMATION

What Oxaliplatin contains
The active ingredient of Oxaliplatin 5 mg/ml Powder for Solution for Infusion is oxaliplatin. The other ingredient is lactose monohydrate.

What Oxaliplatin looks like and contents of the pack
Each vial contains a white powder for solution for infusion containing 50 mg or 100 mg oxaliplatin with lactose monohydrate. The vials are supplied in cartons each containing one vial. Oxaliplatin has to be dissolved before it can be injected into a vein. One ml of reconstituted solution contains oxaliplatin 5 mg.
This leaflet does not contain all the information about your medicine.
If you have any questions or are not sure about anything, ask your doctor or pharmacist.

Marketing Authorisation Holder and Manufacturer
Fresenius Kabi Oncology Plc.
Lion Court, Farnham Road, Bordon
Hampshire GU35 0NF
United Kingdom

Revised: February 2009
UKPAR Oxaliplatin 5mg/ml Powder for Solution for Infusion  
PL 18727/0010

The following information is intended for medical or healthcare professionals only:

INSTRUCTIONS FOR USE, HANDLING AND DISPOSAL

As with other potentially toxic compounds, caution should be exercised when handling and preparing Oxaliplatin solutions.

Instructions for Handling

The handling of this cytotoxic agent by healthcare personnel requires every precaution to guarantee the protection of the handler and his surroundings.

The preparations of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicines used, in conditions that guarantee the integrity of the medicinal product, the protection of the environment and in particular the protection of the personnel handling the medicines, in accordance with the hospital policy. It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area.

Personnel must be provided with appropriate handling materials, notably long sleeved gowns, protection masks, caps, protective goggles, sterile single-use gloves, protective covers for the work area, containers and collection bags for waste.

Faeces and vomit must be handled with care.

Pregnant women must be warned to avoid handling cytotoxic agents.

Any broken container must be treated with the same precautions and considered as contaminated waste. Contaminated waste should be inincinerated in suitably labelled rigid containers. See below chapter "Disposal".

If oxaliplatin powder, reconstituted solution or solution for infusion, should come into contact with skin, wash immediately and thoroughly with water.

If oxaliplatin powder, reconstituted solution or solution for infusion, should come into contact with mucous membranes, wash immediately and thoroughly with water.

Special precautions for administration

- DO NOT use injection equipment containing aluminium
- DO NOT administer undiluted
- Only glucose 5% infusion solution is to be used as a diluent. DO NOT reconstitute or dilute for infusion with saline sodium chloride or chloride containing solutions
- DO NOT mix with any other medicinal products in the same infusion bag or administer simultaneously by the same infusion line
- DO NOT mix with alkaline medicinal products or solutions, in particular 5-fluorouracil, folinic acid preparations containing trental or trental salts of other active substances. Alkaline medicinal products or solutions will adversely affect the stability of oxaliplatin.

Instruction for use with folic acid (FA) (as calcium folinate or disodium folinate)

Oxaliplatin 85 mg/ml intravenous infusion in 250 ml to 500 ml of glucose 5% solution is given at the same time as folic acid (FA) intravenous infusion in glucose 5% solution, over 2 to 6 hours, using a Y-line placed immediately before the site of infusion. These two medicinal products should not be combined in the same infusion bag. Folic acid (FA) must not contain trental or trental as an excipient and must only be diluted using isotonic glucose 5% solution, never in alkaline solutions or sodium chloride or chloride containing solutions.

Instruction for use with 5-fluorouracil (5-FU)

Oxaliplatin should always be administered before flucopyrimidines - i.e. 5-fluorouracil (5-FU). After oxaliplatin administration, flush the line and then administer 5-fluorouracil (5-FU).

For additional information on medicinal products combined with oxaliplatin, see the corresponding manufacturer's summary of product characteristics.

- USE ONLY the recommended solvents (see below).
- Any reconstituted solution that shows evidence of precipitation should not be used and should be destroyed with due regard to legal requirements for disposal of hazardous waste (see below).

Reconstitution of the solution

- Water for Injections or 5% glucose solution should be used to reconstitute the solution.
- For a vial of 40 ml containing 50 mg oxaliplatin: add 10 ml of solvent to obtain a concentration of 5 mg oxaliplatin/ml.
- For a vial of 50 ml containing 100 mg oxaliplatin: add 20 ml of solvent to obtain a concentration of 5 mg oxaliplatin/ml.

From a microbiological and chemical point of view, the reconstituted solution should be diluted immediately with 5% glucose solution. Inspect visually prior to use. Only clear solutions without particles should be used.

The medicinal product is for single use only. Any unused infusion solution should be discarded.

Dilution for intravenous infusion

Withdraw the required amount of reconstituted solution from the vial(s) and then dilute with 250 ml to 500 ml of a 5% glucose solution to give an oxaliplatin concentration between not less than 0.2 mg/ml and 0.6 mg/ml.

Administer by I.V. infusion.

Chemical and physical in-use stability has been demonstrated for 20 °C to 25 °C up to 6 hours and 24 hours at 2 °C to 8 °C. From a microbiological point of view, this infusion preparation should be used immediately.

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 6 hours at 20 °C to 25 °C and 24 hours at 2 °C to 8 °C unless dilution has taken place in controlled and validated aseptic conditions.

Inspect visually prior to use. Only clear solutions without particles should be used.

The medicinal product is for single use only. Any unused infusion solution should be discarded. NEVER use sodium chloride or chloride containing solutions for either reconstitution or dilution.

Infusion

The administration of oxaliplatin does not require prehydration. Oxaliplatin diluted in 250 ml to 500 ml of a 5% glucose solution to give a concentration not less than 0.2 mg/ml must be infused either by peripheral vein or central venous line over 2 to 6 hours. When oxaliplatin is administered with 5-fluorouracil, the oxaliplatin infusion must precede the administration of 5-fluorouracil.

Disposal

Remnants of the medicinal product as well as all materials that have been used for reconstitution, for dilution and administration must be destroyed according to hospital standard procedures applicable to cytotoxic agents in accordance with local requirements related to the disposal of hazardous waste.
For intravenous use only. Must be reconstituted before use. Must be diluted before use. Reconstitute to 5 mg/ml and then dilute as instructed before administration.

For use as directed by the clinician. Read the package leaflet before use. To be administered by I.V. infusion over 2 to 6 hours. Keep out of the reach and sight of children. Cytotoxic. Dispose of any unused solution appropriately.

MA holder: Fresenius Kabi Oncology Plc. Lion Court, Farnham Road Bordon, Hampshire GU35 0NF United Kingdom

R 02/09
### 100 mg Oxaliplatin 5 mg/ml

**Powder for Solution for Infusion**

- **50 ml Vial**
- Each vial of 50 ml contains 100 mg of Oxaliplatin.
- 1 ml of reconstituted solution contains 5 mg Oxaliplatin.
- Lactose monohydrate.
- For intravenous use only.
- Must be reconstituted before use.
- Must be diluted before use.
- Reconstitute to 5 mg/ml and then dilute as instructed before administration.

For use as directed by the clinician. Read the package leaflet before use. To be administered by I.V. infusion over 2 to 6 hours. Keep out of the reach and sight of children. Cytotoxic. Dispose of any unused solution appropriately.

**MA holder:** Fresenius Kabi Oncology Plc.
Lion Court, Farnham Road
Bordon, Hampshire GU35 0NF
United Kingdom

**Batch:** R 02/09
**Exp:**

**Code No.: GO/DRUGS/726/L**

---

**UKPAR Oxaliplatin 5mg/ml Powder for Solution for Infusion**

**PL 18727/0010**
Oxaliplatin 5 mg/ml Powder for Solution for Infusion

Each vial of 30 ml contains 50 mg of Oxaliplatin.
1 ml of reconstituted solution contains 5 mg Oxaliplatin.
Lactose monohydrate.
For intravenous use only.

MA holder:
Preseunis Kabi Oncology Plc.
Lion Court, Farnham Road
Bordon, Hampshire GU35 0NF
United Kingdom

Lot:
Exp:
Code No.: G0/DRUGS/726/L

30 ml Vial
50 mg
50 mg

30 ml Vial
50 mg

Must be reconstituted before use.
Must be diluted before use.
Reconstitute to 5 mg/ml and then dilute as instructed before administration.
For use as directed by the clinician.
Read the package leaflet before use.
To be administered by I.V. infusion over 2 to 6 hours.
Keep out of the reach and sight of children.
Cytotoxic.
Dispose of any unused solution appropriately.

R 0009
PL 18727/0010

POM